Pharma Watch

Category

COVID-19 Vaccine INO-4800 Demonstrates Neutralizing Antibody and T-Cell Immune Responses in Preclinical Models

Inovio Pharmaceuticals (Nasdaq: INO) reported recent preclinical data summaries for their COVID-19 DNA vaccine called INO-4800 demonstrating promising information. Namely, the sponsor’s tests demonstrated robust neutralizing antibody and T cell immune responses...

Ansun Biopharma’s DAS181 Shows Promise in COVID-19 Patients with Respiratory Challenges

Recently, the Wall Street Journal introduced a small, 25-person San Diego-based biotech called Ansun Biophrma (Ansun) reporting on recent success of a drug that cleared COVID-19 symptoms in a small study involving four Chinese patients. With a strong background in...

‘Unprecedented Times call for Bold Moves’ as Competitive Plasma Firms Unite to Battle COVID-19

CSL Behring and Takeda Pharmaceutical Company have initiated an alliance bringing together the world’s leading plasma companies to focus on developing and delivering hyperimmune immunoglobulin to help fight the global war on COVID-19. Led by Australian and American...

Acceleration of First-Patient-First-Visit Study Milestone as Roche Study Investigating Tocilizumab in COVID-19 Pneumonia Patients Enrolls Patients in Spain

Roche recently announce the launch of a global study in collaboration with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) plus standard of care in hospitalized adult...

Regeneron Leverages its Technology Platform, Process and People in the Hopes of Having A COVID-19 Therapy in Trials by Summer

Regeneron and its “VELOCISUITE®” platform was used to develop a treatment for Ebola (REGN-EB3), currently used by the Congolese government to fight that horrific virus. The New York State-based venture has, like many biopharma companies, dedicated a full force...

Mereo BioPharma Completes Type B End-of-Phase 2 Meeting with FDA and Agrees on Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta

Mereo Biopharma announced the successful completion of a Type B End-of-Phase 2 meeting with the U.S. FDA to discuss the development of setrusumab, an anti-sclerostin antibody, for the treatment of children and adolescents with osteogenesis imperfecta (OI). During the...

Pin It on Pinterest